PMID- 20053369
OWN - NLM
STAT- MEDLINE
DCOM- 20100413
LR  - 20131121
IS  - 1096-0333 (Electronic)
IS  - 0041-008X (Linking)
VI  - 244
IP  - 2
DP  - 2010 Apr 15
TI  - Streptozotocin induced activation of oxidative stress responsive splenic cell 
      signaling pathways: protective role of arjunolic acid.
PG  - 114-29
LID - 10.1016/j.taap.2009.12.024 [doi]
AB  - Present study investigates the beneficial role of arjunolic acid (AA) against the 
      alteration in the cytokine levels and simultaneous activation of oxidative stress 
      responsive signaling pathways in spleen under hyperglycemic condition. Diabetes 
      was induced by injection of streptozotocin (STZ) (at a dose of 70 mg/kg body 
      weight, injected in the tail vain). STZ administration elevated the levels of 
      IL-2 as well as IFN-gamma and attenuated the level of TNF-alpha in the sera of 
      diabetic animals. In addition, hyperglycemia is also associated with the 
      increased production of intracellular reactive intermediates resulting with the 
      elevation in lipid peroxidation, protein carbonylation and reduction in 
      intracellular antioxidant defense. Investigating the oxidative stress responsive 
      cell signaling pathways, increased expressions (immunoreactive concentrations) of 
      phosphorylated p65 as well as its inhibitor protein phospho IkappaBalpha and 
      phosphorylated mitogen activated protein kinases (MAPKs) have been observed in 
      diabetic spleen tissue. Studies on isolated splenocytes revealed that 
      hyperglycemia caused disruption of mitochondrial membrane potential, elevation in 
      the concentration of cytosolic cytochrome c as well as activation of caspase 3 
      leading to apoptotic cell death. Histological examination revealed that diabetic 
      induction depleted the white pulp scoring which is in agreement with the reduced 
      immunological response. Treatment with AA prevented the hyperglycemia and its 
      associated pathogenesis in spleen tissue. Results suggest that AA might act as an 
      anti-diabetic and immunomodulatory agent against hyperglycemia.
CI  - Copyright 2009 Elsevier Inc. All rights reserved.
FAU - Manna, Prasenjit
AU  - Manna P
AD  - Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VIIM, 
      Calcutta-700054, West Bengal, India.
FAU - Ghosh, Jyotirmoy
AU  - Ghosh J
FAU - Das, Joydeep
AU  - Das J
FAU - Sil, Parames C
AU  - Sil PC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20100104
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Plant Extracts)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Triterpenes)
RN  - 465-00-9 (arjunolic acid)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/metabolism/*prevention & control
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - Male
MH  - Oxidative Stress/drug effects/*physiology
MH  - Plant Bark
MH  - Plant Extracts/pharmacology/therapeutic use
MH  - Rats
MH  - Reactive Oxygen Species/metabolism
MH  - Signal Transduction/drug effects/*physiology
MH  - Spleen/drug effects/*metabolism
MH  - Streptozocin/antagonists & inhibitors/*toxicity
MH  - Terminalia
MH  - Triterpenes/*pharmacology/therapeutic use
EDAT- 2010/01/08 06:00
MHDA- 2010/04/14 06:00
CRDT- 2010/01/08 06:00
PHST- 2009/03/23 00:00 [received]
PHST- 2009/12/02 00:00 [revised]
PHST- 2009/12/17 00:00 [accepted]
PHST- 2010/01/08 06:00 [entrez]
PHST- 2010/01/08 06:00 [pubmed]
PHST- 2010/04/14 06:00 [medline]
AID - S0041-008X(09)00531-6 [pii]
AID - 10.1016/j.taap.2009.12.024 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 2010 Apr 15;244(2):114-29. doi: 
      10.1016/j.taap.2009.12.024. Epub 2010 Jan 4.